Literature DB >> 7666531

The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle.

J B Jowett1, V Planelles, B Poon, N P Shah, M L Chen, I S Chen.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection causes profound immunological defects in afflicted patients. Various mechanisms have been proposed to account for the immune dysfunction in AIDS ultimately leading to loss of CD4+ T cells, including HIV-1 envelope-mediated syncytium formation, apoptosis, and cytokine modulation. Here we present results which suggest a novel hypothesis for T-cell dysfunction. We show, using HIV-1 bearing a novel cell surface reporter gene, that infected cells are unable to progress normally through the cell cycle and became arrested in the G2 + M phase. Furthermore, we identify the HIV-1 vpr gene product as being both necessary and sufficient for eliciting this cell cycle arrest. Cell cycle arrest induced by Vpr correlates with an increase in the hyperphosphorylated (inactive) form of the cyclin-dependent serine/threonine kinase CDC2, consistent with an arrest of cells at the boundary of G2 and M.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666531      PMCID: PMC189529     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages.

Authors:  N Hattori; F Michaels; K Fargnoli; L Marcon; R C Gallo; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Human immunodeficiency virus vpr product is a virion-associated regulatory protein.

Authors:  E A Cohen; G Dehni; J G Sodroski; W A Haseltine
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

Review 3.  Universal control mechanism regulating onset of M-phase.

Authors:  P Nurse
Journal:  Nature       Date:  1990-04-05       Impact factor: 49.962

4.  Identification of HIV-1 vpr product and function.

Authors:  E A Cohen; E F Terwilliger; Y Jalinoos; J Proulx; J G Sodroski; W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

5.  Mutational analysis of the human immunodeficiency virus vpr open reading frame.

Authors:  K Ogawa; R Shibata; T Kiyomasu; I Higuchi; Y Kishida; A Ishimoto; A Adachi
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  Human immunodeficiency virus vpr gene encodes a virion-associated protein.

Authors:  X Yuan; Z Matsuda; M Matsuda; M Essex; T H Lee
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

7.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Cyclin activation of p34cdc2.

Authors:  M J Solomon; M Glotzer; T H Lee; M Philippe; M W Kirschner
Journal:  Cell       Date:  1990-11-30       Impact factor: 41.582

9.  Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor.

Authors:  M Jaskólski; A G Tomasselli; T K Sawyer; D G Staples; R L Heinrikson; J Schneider; S B Kent; A Wlodawer
Journal:  Biochemistry       Date:  1991-02-12       Impact factor: 3.162

10.  Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: identification of major phosphorylation sites.

Authors:  W Krek; E A Nigg
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598

View more
  239 in total

1.  Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73.

Authors:  B E Sawaya; K Khalili; J Gordon; A Srinivasan; M Richardson; J Rappaport; S Amini
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Efficient DNA transfection mediated by the C-terminal domain of human immunodeficiency virus type 1 viral protein R.

Authors:  A Kichler; J C Pages; C Leborgne; S Druillennec; C Lenoir; D Coulaud; E Delain; E Le Cam; B P Roques; O Danos
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons.

Authors:  S C Piller; G D Ewart; D A Jans; P W Gage; G B Cox
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Vpr-mediated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A.

Authors:  M Hrimech; X J Yao; P E Branton; E A Cohen
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

5.  Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging.

Authors:  Y Jenkins; P V Sanchez; B E Meyer; M H Malim
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  The first HxRxG motif in simian immunodeficiency virus mac239 Vpr is crucial for G(2)/M cell cycle arrest.

Authors:  Sandra M Mueller; Sabine M Lang
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest.

Authors:  M P Sherman; C M de Noronha; D Pearce; W C Greene
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Mechanism of human immunodeficiency virus type 1 localization in CD4-negative thymocytes: differentiation from a CD4-positive precursor allows productive infection.

Authors:  S G Kitchen; C H Uittenbogaart; J A Zack
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.

Authors:  Erik S Zimmerman; Junjie Chen; Joshua L Andersen; Orly Ardon; Jason L Dehart; Jana Blackett; Shailesh K Choudhary; David Camerini; Paul Nghiem; Vicente Planelles
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

10.  The C-terminal domain of the HIV-1 regulatory protein Vpr adopts an antiparallel dimeric structure in solution via its leucine-zipper-like domain.

Authors:  Sarah Bourbigot; Hervé Beltz; Jérôme Denis; Nelly Morellet; Bernard P Roques; Yves Mély; Serge Bouaziz
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.